Experts suggest that a single quarter does not make a financial history and the prudent investor should not flee at the first whiff of smoke, however 2007 was not a investor confindence building year for Angiodynamics. Reaching of low stock price of 9.95 on March 10, 2008, the outlook was bleak.
However F4Q08 (quarter ending 5/31/08) results were excellent. Despite settling a patent infringement case with VNUS medical in June. Seeking alpha has the earnings call transcripts. On this news, the stock climbed to 16.19 on Friday July 25, 2008.
Recently, Forbes.com ranked ANGO 11th on its list of 200 best small companies. Things are looking up. The question is our the bad times behind and is there more upside to come with ANGO's strong position in the venous space with it Diomed acquisition and settlement of the VNUS Medical litigation. Is it a buy or sell
Comments